Activity of Pradofloxacin against Porphyromonas and Prevotella spp. Implicated in Periodontal Disease in Dogs: Susceptibility Test Data from a European Multicenter Study

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 2008, p. 2149–2155 0066-4804/08/$08.00⫹0 doi:10.1128/AAC.00019-08 Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Vol. 52, No. 6

Activity of Pradofloxacin against Porphyromonas and Prevotella spp. Implicated in Periodontal Disease in Dogs: Susceptibility Test Data from a European Multicenter Study䌤 Bernd Stephan,1 Heinrich A. Greife,1 Andrew Pridmore,2 and Peter Silley3,4* Bayer HealthCare AG, Animal Health Division, Leverkusen D-51368, Germany1; Don Whitley Scientific Ltd., Shipley, West Yorkshire BD17 7SE, United Kingdom2; MB Consult Limited, Lymington SO41 3TQ, United Kingdom3; and Department of Biomedical Sciences, University of Bradford, Bradford, United Kingdom4 Received 5 January 2008/Returned for modification 26 March 2008/Accepted 5 April 2008

Collaborating veterinarians from five European countries collected subgingival bacterial samples from dogs exhibiting clinical periodontal disease. Sterile endodontic paper points were used for collection of the samples, which were transported to a central laboratory for susceptibility testing. Anaerobic bacteria were isolated and Porphyromonas and Prevotella isolates identified to the species level; susceptibility to pradofloxacin and metronidazole was determined using the CLSI agar dilution methodology. A total of 630 isolates, 310 of Porphyromonas spp. and 320 of Prevotella spp., were isolated. Pradofloxacin MIC data for all isolates were in the range of